Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain...( Kingfisher's Revolutionary Device De...),Health

Kingfisher's Revolutionary Device Designed to Improve Quality of Life for

Patients Suffering From Chronic Pain

ALBUQUERQUE, New Mexico, March 31 /PRNewswire/ -- Kingfisher Americas, a healthcare company focused on improving patient quality of life, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market KFH Energy in the United States. The patented, high-tech medical device is intended to improve upon quality of life for sufferers of chronic pain associated with post-polio syndrome, fibromyalgia, multiple sclerosis, and chronic fatigue syndrome.

"We are thrilled to introduce KFH Energy to physicians, specialists, and patients throughout the United States," said Dr. Henk Snyman, CEO and co-founder of Kingfisher Healthcare, the parent company of Kingfisher Americas. "Our clinical research on post-polio patients yielded dramatic improvements, and we are eager to address the strong population of chronic pain patients in the U.S. With the proven success of KFH Energy, we anticipate that this technology will be the first in a suite of natural energy devices for a variety of treatments."

KFH Energy utilizes a unique form of micro current electrotherapy called Bio-Electric Stimulation Therapy (BEST), which is designed to enhance the body's physiological processes. Intended for home use, KFH Energy encapsulates this novel technology in a hand-held device. Its sleek and modern design elements, including the patented touch-screen panel, make the device both convenient and easy to use. KFH Energy received CE mark in Europe in September 2007.

"There is a growing demand among individuals with chronic pain for alternative treatments to improve their condition," said Herb Whitaker, CEO of Kingfisher Americas. "We are excited to have this device available in the States and are committed to improving the lives of those who have been sidelined as a result of symptoms." '/>"/>